Press release 📈 Stocks 🌍 Sweden

Enorama Pharma Secures 2,500,000 USD Loan to Restore Equity and Avoid Liquidation

Enorama Pharma secures a 2,500,000 USD loan from DS Global, enabling the company to restore its equity above half of the registered share capital and avoid liquidation proceedings.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: ENPH ↑ 7/10 (75% confidence).

📊 Affected Assets (1)

ENPH
Bullish 🤖 75%
📅 Short-term 🌍 SE · Explicit

The main owner DS Global lends USD 2,500,000 interest-free (optionally 9% p.a. if the EGM approves), maturing 31 December 2027, repayable only via share conversion at 0.4 SEK per share. This lets the loan count as equity, restoring equity above half the registered share capital, so the board can propose continued operations instead of liquidation at the second control meeting. For a company under a control balance sheet since 13 February 2026, survival is decisive, but dilution at the 0.4 SEK conversion price and the EGM approval condition temper the effect.

Catalysts
  • ▲ USD 2,500,000 loan agreement signed today, 13 November 2026, with main owner DS Global
  • ▲ Equity restored above half of registered share capital, removing the liquidation trigger
Risk Factors
  • ▼ The 9% annual interest requires approval at the extraordinary shareholders' meeting
  • ▼ Possible repayment by set-off in an issue at 0.4 SEK per share implies significant dilution

🧭 Full analysis of these assets

🎯 Key Takeaways

  • Enorama Pharma signed a 2,500,000 USD loan agreement with DS Global on 13 November 2026.
  • The loan enables the company to restore equity above half of the registered share capital, removing the liquidation trigger from 13 February 2026.
  • The board intends to propose continued operations at the second control meeting.
  • A conditional agreement proposes a 9% annual interest rate, subject to approval at an extraordinary general meeting.
  • The loan matures on 31 December 2027 and allows for repayment via share conversion at 0.4 SEK per share.

📝 Executive Summary

Enorama Pharma has entered a 2,500,000 USD loan agreement with its main shareholder, DS Global, to restore its equity position. The capital injection allows the board to propose continued operations at the upcoming second control meeting, effectively reversing the liquidation risk triggered on 13 February 2026.

❓ FAQ

Why is this loan important for Enorama Pharma shareholders?

Because the loans from DS Global can be counted as equity, the company's equity is restored above half of the registered share capital, and the board intends to propose continued operations rather than liquidation at the second control meeting.

What does the loan cost the company?

The loan runs interest-free until 31 December 2027, but an add-on agreement, conditional on shareholder approval, introduces 9% annual interest from the day of the meeting; repayment is possible early or via conversion to shares at 0.4 SEK per share.